The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Safety Review of Adult Clinical Trial Experience with Lamotrigine
Abstract
To date approximately 4000 adults > 12 years of age have been treated with lamotrigine in Glaxo Wellcome sponsored clinical trials. Review of the data from these trials shows lamotrigine to be effective and well tolerated in both add-on and monotherapy treatment. Safety of lamotrigine was comparable to that of other anticonvulsants in add-on controlled clinical trials. In addition, fewer than half the number of patients in monotherapy studies who were taking lamotrigine discontinued treatment because of adverse events compared to those taking carbamazepine and phenytoin. Most of the reported adverse events seen in lamotrigine treated patients in all studies were judged by the investigator to be mild or moderate in severity; few of the adverse events resulted in the withdrawal of patients from studies. Analysis of vital signs and clinical laboratory data have revealed no undesirable effect of lamotrigine on major systems of the body. The most concerning adverse event has been rash. In clinical trials, this has most often been limited to a simple morbilliform rash which is not associated with evidence of systemic involvement. The incidence of Stevens-Johnson syndrome (SJS) in clinical trials is approximately 1 in 1000. Rash associated with lamotrigine has typically occurred within the first 8 weeks of treatment. Data from clinical trials clearly point to exceeding currently recommended dosage guidelines of lamotrigine and co-administration of valproic acid (valproate sodium) as risk factors for rash. Early in 1997, Glaxo Wellcome strengthened existing warnings in the product label regarding the risk of rash and reinforced the importance of adherence to administration guidelines in an effort to reduce the incidence of rash.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 10% of patients being treated with lamotrigine will experience a non‐serious rash, with 0.3%‐1% developing a serious rash such as toxic epidermal necrolysis and SJS,870 although for those initiated on a dose of 25 mg with a gradual titration increasing the dose by 25 mg biweekly, the risk of developing serious rash may be as low as 0.02% or 1 in 5000.871”
Citations
Cites
Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
Brodie, M. J., UK Lamotrigine/Carbamazepine Monotherapy Trial Group, Richens, A., & Yuen, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90581-2 · Cited by 615 · cited 2×
“epine[19,20] and phenytoin,[21] respectively, as active comparator drugs (table V).”
BackgroundLamotrigine substitution study: evidence for synergism with sodium valproate?
Brodie, M. J., & Yuen, A. W. C. (1997) · Epilepsy Research · doi:10.1016/s0920-1211(96)01007-8 · Cited by 379 · cited 2×
“[28] Because of the concern over the increased risk of rash formation, the manufacturer changed the package label in 1997 to include very strict dosage guidelines addressing both dose escalation and concomitant use with valproic acid.”
BackgroundLamotrigine for Generalized Seizures Associated with the Lennox–Gastaut Syndrome
Motte, J., Trevathan, E., Arvidsson, J. F. V., Barrera, M. N., Mullens, E. L., & Manasco, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712183372504 · Cited by 359
Self-citationThe New Antiepileptic Drugs: A Systematic Review of Their Efficacy and Tolerability
Marson, A. G., Kadir, Z. A., Hutton, J. L., & Chadwick, D. W. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01251.x · Cited by 347 · cited 2×
“A recent meta-analysis[24] of randomised placebo controlled trials with lamotrigine revealed the following odds ratios (incidence with lamotrigine : incidence with placebo) and 95% confidence intervals for specific adverse events: • ataxia 2.”
ResultOutcomes of Add‐on Treatment with Lamotrigine in Partial Epilepsy
Smith, D., Baker, G., Davies, G., Dewey, M., & Chadwick, D. W. (1993) · Epilepsia · doi:10.1111/j.1528-1157.1993.tb02417.x · Cited by 330 · cited 1×
“[4-18] In adult monotherapy trials, lamotrigine has been shown to be at least as effective as carbamazepine or phenytoin monotherapy and to be significantly better tolerated.”
BackgroundLamotrigine: A Review of its Pharmacological Properties and Clinical Efficacy in Epilepsy
Goa, K. L., Ross, S. R., & Chrisp, P. (1993) · Drugs · doi:10.2165/00003495-199346010-00009 · Cited by 307 · cited 1×
“These findings have been previously reviewed[22,23] and are not reviewed further in this paper.”
BackgroundTennis, P., & Stern, R. S. (1997) · Neurology · doi:10.1212/wnl.49.2.542 · Cited by 261
Xie, X., Lancaster, B., Peakman, T., & Garthwaite, J. (1995) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/bf00373920 · Cited by 249
Messenheimer, J., Ramsay, R. E., Willmore, L. J., Leroy, R. F., Zielinski, J., Mattson, R., Pellock, J. M., Valakas, A. M., Womble, G., & Risner, M. (1994) · Epilepsia · doi:10.1111/j.1528-1157.1994.tb02920.x · Cited by 217
Self-citationLamotrigine versus Placebo in the Prophylaxis of Migraine with and Without aura
Steiner, T., Findley, L., & Yuen, A. (1997) · Cephalalgia · doi:10.1046/j.1468-2982.1997.1702109.x · Cited by 214 · cited 1×
“In a placebo controlled monotherapy study of lamotrigine as a therapy for migraine treatment,[27] not discussed so far, withdrawal because of rash was reduced to placebo levels when the starting dosage was changed halfway through enrollment from a fixed dose of 200 mg/day to a gradual escalation over a 4 week time per…”
Background
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Adverse effects of antiepileptic drugs
Perucca, P., & Gilliam, F. G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70153-9 · Cited by 694
Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision)
Hirschfeld, R. M. A., Bowden, C. L., Gitlin, M. J., Keck, P. E., Perlis, R. H., Suppes, T., Thase, M. E., & Wagner, K. D. (2003) · Focus · doi:10.1176/foc.1.1.64 · Cited by 585
Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics
Mockenhaupt, M., Messenheimer, J., Tennis, P., & Schlingmann, J. (2005) · Neurology · doi:10.1212/01.wnl.0000156354.20227.f0 · Cited by 399
Self-citationYatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
“With decreases in the recommended starting dose to 25 mg, and following a gradual titration, with 25 mg increments weekly, the risk of serious rash may be as low as 1 in 5000 (353).”
Background
Metadata
- Authors
- Messenheimer, J., Mullens, E. L., Giorgi, L., & Young, F.
- Venue
- Drug Safety
- Published
- 1998
- Volume
- 18
- Issue
- 4
- Pages
- 281-296
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W1989801730
- Cited by
- 252
- References
- 27
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 6 · 2019: 33 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 7 · 2013: 6 · 2012: 8
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- lamotrigine, adverse drug reactions, rash, Stevens-Johnson syndrome, morbilliform rash, valproic acid, dosing recommendations, carbamazepine, phenytoin, epilepsy, drug safety labeling
- MeSH terms
- Lamotrigine, Adolescent, Adult, Anticonvulsants, Calcium Channel Blockers, Drug Therapy, Combination, Exanthema, Female, Humans, Male, Regression Analysis, Risk Factors, Seizures, Triazines, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety Review of Adult Clinical Trial Experience with Lamotrigine. https://app.cochat.ai/papers/10.2165/00002018-199818040-00004
- The paper
- Messenheimer, J., Mullens, E. L., Giorgi, L., & Young, F. (1998). Safety Review of Adult Clinical Trial Experience with Lamotrigine. Drug Safety. https://doi.org/10.2165/00002018-199818040-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.